Literature DB >> 33992627

Reproducibility and accuracy of a target motion mitigation technique for dose-escalated prostate stereotactic body radiotherapy.

Carlo Greco1, Joep Stroom2, Sandra Vieira2, Dalila Mateus2, Maria João Cardoso2, Ana Soares2, Oriol Pares2, Nuno Pimentel2, Vasco Louro2, Beatriz Nunes2, Justyna Kociolek2, Zvi Fuks3.   

Abstract

BACKGROUND AND
PURPOSE: To quantitate the accuracy, reproducibility and prostate motion mitigation efficacy rendered by a target immobilization method used in an intermediate-risk prostate cancer dose-escalated 5×9Gy SBRT study.
MATERIAL AND METHODS: An air-inflated (150 cm3) endorectal balloon and Foley catheter with three electromagnetic beacon transponders (EBT) were used to mitigate and track intra-fractional target motion. A 2 mm margin was used for PTV expansion, reduced to 0 mm at the interface with critical OARs. EBT-detected ≥ 2 mm/5 s motions mandated treatment interruption and target realignment prior to completion of planned dose delivery. Geometrical uncertainties were measured with an in-house ESAPI script.
RESULTS: Quantitative data were obtained in 886 sessions from 189 patients. Mean PTV dose was 45.8 ± 0.4 Gy (D95 = 40.5 ± 0.4 Gy). A mean of 3.7 ± 1.7 CBCTs were acquired to reach reference position. Mean treatment time was 19.5 ± 12 min, 14.1 ± 11 and 5.4 ± 5.9 min for preparation and treatment delivery, respectively. Target motion of 0, 1-2 and >2 mm/10 min were observed in 59%, 30% and 11% of sessions, respectively. Temporary beam-on hold occurred in 7.4% of sessions, while in 6% a new reference CBCT was required to correct deviations. Hence, all sessions were completed with application of the planned dose. Treatment preparation time > 15 min was significantly associated with the need of a second reference CBCT. Overall systematic and random geometrical errors were in the order of 1 mm.
CONCLUSION: The prostate immobilization technique explored here affords excellent accuracy and reproducibility, enabling normal tissue dose sculpting with tight PTV margins.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  On-line tracking; Prostate cancer; SBRT; Target motion mitigation; Urethral sparing

Year:  2021        PMID: 33992627     DOI: 10.1016/j.radonc.2021.05.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.

Authors:  Carlo Greco; Oriol Pares; Nuno Pimentel; Vasco Louro; Beatriz Nunes; Justyna Kociolek; Joep Stroom; Sandra Vieira; Dalila Mateus; Maria Joao Cardoso; Ana Soares; Joao Marques; Elda Freitas; Graça Coelho; Zvi Fuks
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 5.738

2.  Improvement in bladder volume reproducibility using A-mode portable ultrasound bladder scanner in moderate-hypofractionated volumetric modulated arc therapy for prostate cancer patients.

Authors:  Shingo Ohira; Riho Komiyama; Naoyuki Kanayama; Kayo Sakai; Takero Hirata; Kento Yoshikata; Yoshihiro Ueda; Masayoshi Miyazaki; Masashi Nakayama; Masahiko Koizumi; Koji Konishi
Journal:  J Appl Clin Med Phys       Date:  2022-02-02       Impact factor: 2.102

3.  Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy.

Authors:  Miriam Eckl; Gustavo R Sarria; Sandra Springer; Marvin Willam; Arne M Ruder; Volker Steil; Michael Ehmann; Frederik Wenz; Jens Fleckenstein
Journal:  Radiat Oncol       Date:  2021-08-04       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.